ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1908

Clinical and Imaging Features of Haemochromatosis Arthropathy – a Systematic Literature Review and Meta- Analysis

Svenja Engelhardt1, Sabine Buroh2, Guido Schwarzer3, Andreas Kerschbaumer4, Axel Braner5, Mathilde Herber6, Pedro Machado7, Patrick Kiely8 and Stephanie Finzel9, 1University of Freiburg, Freiburg im Breisgau, Germany, 2Library of the Medical Center - University of Freiburg, Faculty of Medicine, Library of the Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, Freiburg, Germany, 3University of Freiburg, Freiburg, Germany, Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany, Freiburg, Germany, Freiburg, Germany, 4Stanford University / Medical University of Vienna, Stanford, CA, 5MVZ Aschaffenburg, Aschaffenburg, Germany, Frankfurt, Germany, 6Strasbourg Centre University, Strasbourg, France, Department of Internal Medicine, Strasbourg, France, Strasbourg, France, 7Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 8St George's University Hospitals NHS Foundation Trust, London, United Kingdom, 9Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Meeting: ACR Convergence 2025

Keywords: Bioinformatics, Biostatistics, Epidemiology, Imaging, Musculoskeletal Examination

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1877–1913) Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Haemochromatosis arthropathy (HA) has been little researched to date. Arthropathy frequently is amongst thefirst clinical manifestations of haemochromatosis, but might be overlooked or misdiagnosed as being of different origin, which impacts significantly on the patient’s joint function and health due to delayed diagnose and therapy initiation. This SLR aimed to summarise the imaging and clinical features of haemochromatosis arthropathy to inform the development of EULAR classification criteria for HA.

Methods: We performed a systematic literature review by searching Medline (PubMed, Ovid), the Cochrane Library andEmbase, as well as conference abstract databases. Only original articles describing clinical and/or imaging features of HA (without language restriction or year of publication) were eligible for inclusion. After article and abstract screening, we assessed articles in detail for eligibility based on study quality and adequate reporting of outcomes. Random intercept logistic regression was utilised (using R, version 4.2.1) to calculate individual probabilities of outcomes assessed.

Results: Of 595 articles initially screened, 52 were analysed in detail and 36 studies were found appropriate for final analysis (Figure 1). The most common ineligibility reasons during detailed article review were poor study quality and insufficient reporting of outcomes. The most prevalent clinical characteristics were focussed on the MCP2 and MCP3 joints, with limited range of motion (pooled proportion: 62%, Figure 2 A+B), bony enlargement (48%) and pain (41%). With regards to imaging characteristics, MCP joints 2/3 showed the highest frequency of subchondral cysts (MCP2 and MCP3 52%, respectively), joint space narrowing (MCP2: 62% and MCP3 62%, respectively, Figure 2 C+D), and osteophytes (MCP2: 49%; MCP3: 52%). Chondrocalcinosis prevailed in the knee (29%), and subchondral sclerosis in the hip in 61%. Considerable heterogeneity (I²) across most meta-regressions was identified (p< 0.01 for all analyses except for bony enlargement in MCP2/3 and subchondral sclerosis of the hip). Table 1 summarizes the detailed results and estimates of the meta-regression analyses.

Conclusion: Our SLR identified the most commonly reported clinical characteristics and imaging patterns of HA joint involvement. As expected for this rare disease, only a limited number of articles were identified and most studies described small numbers of patients, with significant variability of outcomes, also leading to high heterogeneity in our analyses. This SLR summarizes the current evidence on clinical and imaging features important in HA, demonstrating the unmet need of developing classification criteria in patients with HA.

Supporting image 1Figure 1: Prisma flow diagram

Supporting image 2Figure 2 A, B: Forest plot illustrating pooled effect estimates for limited rang of joint movement in (A) metacarpophalangeal (MCP) 2 and (B) MCP 3 joints.

Figure 2 C, D: Forest plot illustrating pooled effect estimates for radiographic joint space narrowing in (A) metacarpophalangeal (MCP) 2 and (B) MCP 3 joints.

Supporting image 3Table 1: Detailed results of clinical and imaging findings showing the pooled proportions derived from random intercept logistic regression analyses on reported outcomes.


Disclosures: S. Engelhardt: None; S. Buroh: None; G. Schwarzer: None; A. Kerschbaumer: AbbVie/Abbott, 2, Boehringer-Ingelheim, 12, Travel, Eli Lilly, 12, Travel, Janssen, 2, 6, Pfizer, 6, Stada, 6, UCB, 2, 6, 12, Travel; A. Braner: None; M. Herber: None; P. Machado: AbbVie/Abbott, 2, 6, Eli Lilly, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; P. Kiely: Alfasigma, 6, Eli Lilly, 12, Sponsorship to attend educational meetings; S. Finzel: AbbVie/Abbott, 6, Alfasigma/Galapagos, 6, 12, meeting or travel grant, AstraZeneca, 2, Biotest, 6, 12, meeting or travel grant, Celltrion, 6, Chugai, 6, Eli Lilly, 12, meeting or travel grant, GlaxoSmithKlein(GSK), 2, 6, Johnson&Johnson, 2, 6, 12, meeting or travel grant, Novartis, 2, 6, 12, meeting or travel grant, NovoNordisk, 2, Sobi, 12, meeting or travel grant, UCB, 2, 6, 12, meeting or travel grant.

To cite this abstract in AMA style:

Engelhardt S, Buroh S, Schwarzer G, Kerschbaumer A, Braner A, Herber M, Machado P, Kiely P, Finzel S. Clinical and Imaging Features of Haemochromatosis Arthropathy – a Systematic Literature Review and Meta- Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clinical-and-imaging-features-of-haemochromatosis-arthropathy-a-systematic-literature-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-imaging-features-of-haemochromatosis-arthropathy-a-systematic-literature-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology